EICHOR
● Active Not Recruiting
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Condition: Retinitis Pigmentosa (RP) · Usher Syndrome Type 2 · Deaf Blind · Sponsor: Laboratoires Thea
About this study
The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (26)
| The University of California, San Francisco | San Francisco, California, United States | — |
| Bascom Palmer Eye Institute/University of Miami | Miami, Florida, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| Massachusetts Eye and Ear | Boston, Massachusetts, United States | — |
| University of Michigan- Kellogg Eye Center | Ann Arbor, Michigan, United States | — |
| Casey Eye Institute, Oregon Health & Science University | Portland, Oregon, United States | — |
| University of Pennsylvania, Scheie Eye Institute | Philadelphia, Pennsylvania, United States | — |
| Retina Foundation of the Southwest | Dallas, Texas, United States | — |
| Baylor College of Medicine | Houston, Texas, United States | — |
| University of Wisconsin- Madison | Madison, Wisconsin, United States | — |
| Ghent University Hospital | Ghent, Belgium | — |
| INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte | Belo Horizonte, Brazil | — |
+ 14 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06627179